New Delhi: Akums Drugs and Pharmaceuticals, a leader in contract development and manufacturing, has launched Dapagliflozin + Pioglitazone tablets; an advanced combination therapy designed to tackle the growing challenge of diabetes management. While conventional treatments often fall short in maintaining stable blood sugar levels, this dual-action formulation offers a more potent solution for individuals struggling with existing metformin-based regimens. Approved by the Drugs Controller General of India (DCGI), it goes beyond glycemic control, overcoming broader obstacles associated with diabetes care.
This dual-action therapy combines two complementary mechanisms of action. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management. Pioglitazone, on the other hand, augments insulin sensitivity in key tissues, such as muscles and the liver, helping combat the root issue of insulin resistance. Together, they provide sustained results while minimising risks like hypoglycemia and weight gain, which are common hurdles in diabetes care.
Compared to monotherapy, this dual approach ensures more comprehensive blood sugar regulation by addressing multiple pathways simultaneously. While single-drug regimens may provide partial benefits, the combined action of Dapagliflozin and Pioglitazone offers superior control, reducing fluctuations in glucose levels more effectively. Moreover, dual therapy lowers the likelihood of treatment failure, ensuring long-term stability without necessitating frequent medication adjustments. Its once-daily dosing further enhances adherence, making diabetes management simpler and seamless for patients.
Type 2 diabetes mellitus (T2DM) has emerged as a significant health challenge in India, with over 77 million adults affected and an additional 25 million on the brink of developing the condition, as per World Health Organisation estimates. What’s more alarming is that a significant portion of these cases remain undetected, often leading to severe complications. By 2045, this number is projected to climb to an astounding 134 million, highlighting the critical need for impactful interventions.
Commenting on the launch, Mr. Sandeep Jain, Managing Director of Akums Drugs and Pharmaceuticals, stated, “The rise in diabetes cases in our country calls for novel and accessible solutions. By introducing Dapagliflozin + Pioglitazone tablets, we aim to equip healthcare providers with an advanced treatment option that caters to the diverse needs faced by patients. Our goal is to deliver therapies that make a real difference in people’s lives.”
Adding to this, Mr. Sanjeev Jain, Managing Director of Akums, noted, “The fight against diabetes requires a collaborative effort between healthcare providers, patients, and pharmaceutical innovators. Managing the condition often presents significant lifestyle hurdles for those affected. At Akums, we are committed to elevating well-being and enabling sound health outcomes. Backed by robust research, this dual-action therapy is developed to progress patient outcomes and overall well-being.”
Type 2 diabetes disrupts the way the body uses glucose for energy, impairing insulin function and leading to elevated blood sugar levels if untreated. Over time, it can cause serious health issues, particularly affecting the nerves and blood vessels. Early diagnosis is important to mitigating the long-term effects, and regular medical check-ups and blood tests are essential for timely detection and management.
As diabetes continues to burden healthcare systems and individuals alike, Akums is setting a benchmark in pharmaceutical innovation, providing the medical community with solutions that tackle both the complexities and consequences of this growing epidemic.
